drugset / Trial / NCT02258282

Safety and Efficacy of Etanercept in Patients With Psoriasis

NCT02258282

Unknown 80 enrolled Chengdu PLA General Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to traditional DMARDs.

Timeline

Start
2014-05
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg

Indications